T. Rowe Price Associates
LYEL icon

T. Rowe Price Associates’s Lyell Immunopharma LYEL Stock Holding History

T. Rowe Price Associates’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Buy
30,657
+17,529
+134% +$317K ﹤0.01% 2686
2026
Q1 		$264K Hold
13,128
– – ﹤0.01% 2739
2025
Q4 		$405K Hold
13,128
– – ﹤0.01% 2490
2025
Q3 		$214K Sell
13,128
-292,931
-96% -$3.35M ﹤0.01% 2769
2025
Q2 		$2.71M Sell
306,059
-17,883
-6% -$163K ﹤0.01% 1513
2025
Q1 		$3.49M Sell
323,942
-21,595
-6% -$265K ﹤0.01% 1371
2024
Q4 		$4.42M Sell
345,537
-22,077
-6% -$438K ﹤0.01% 1323
2024
Q3 		$10.1M Sell
367,614
-26,004
-7% -$764K ﹤0.01% 1142
2024
Q2 		$11.4M Buy
393,618
+57,044
+17% +$2.72M ﹤0.01% 1088
2024
Q1 		$15M Buy
336,574
+4,630
+1% +$198K ﹤0.01% 1043
2023
Q4 		$12.9M Sell
331,944
-2,366
-0.7% -$85.2K ﹤0.01% 1047
2023
Q3 		$9.83M Sell
334,310
-73,745
-18% -$3.5M ﹤0.01% 1075
2023
Q2 		$26M Buy
408,055
+209,688
+106% +$11.6M ﹤0.01% 868
2023
Q1 		$9.36M Buy
198,367
+14,583
+8% +$780K ﹤0.01% 1071
2022
Q4 		$12.8M Sell
183,784
-81,546
-31% -$8.1M ﹤0.01% 1013
2022
Q3 		$38.9M Sell
265,330
-1,045
-0.4% -$141K 0.01% 726
2022
Q2 		$34.7M Sell
266,375
-8,321
-3% -$850K ﹤0.01% 994
2022
Q1 		$27.7M Buy
274,696
+17,631
+7% +$2.14M ﹤0.01% 1143
2021
Q4 		$39.8M Buy
257,065
+74,101
+41% +$16.5M ﹤0.01% 1081
2021
Q3 		$54.2M Buy
182,964
+57,964
+46% +$17.4M 0.01% 975
2021
Q2 		$40.6M Buy
+125,000
New +$41M ﹤0.01% 1105

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

T. Rowe Price Associates's LYEL Position: Q2 2026 in Review

T. Rowe Price Associates increased its Lyell Immunopharma (LYEL) stake by 134% in Q2 2026, buying an estimated $317K and bringing the position to 30,657 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #2686.

T. Rowe Price Associates first reported a position in LYEL in Q2 2021 and has held it in 21 quarters since. The position peaked at $54.2M in Q3 2021. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • T. Rowe Price Associates held 30,657 shares of Lyell Immunopharma worth $431K as of Q2 2026.
  • T. Rowe Price Associates bought 17,529 Lyell Immunopharma shares in Q2 2026, an estimated $317K.
  • Lyell Immunopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2686 holding.
  • T. Rowe Price Associates first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Lyell Immunopharma position peaked at $54.2M in Q3 2021.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.